Notice of Intent to Sole Source – Intera 3000 Hepatic Artery Infusion Pumps (NIH/NCI)

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

HEALTH AND HUMAN SERVICES, DEPARTMENT OF

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98026Q00079

NAICS

339112 - Surgical and Medical Instrument Manufacturing

Classification Code

6515

Additional Details
Set Aside

NONE

Place of Performance

UNITED STATES

SourceSAM
Documents1
The U.S. Department of Health and Human Services (HHS), through the National Institutes of Health (NIH) and its National Cancer Institute (NCI) Center for Cancer Research (CCR) Surgical Oncology Program (SOP), has issued a Special Notice of Intent to award a sole source, firm-fixed-price contract to Inter Oncology Inc. for the procurement of Intera 3000 Hepatic Artery Infusion Pumps. This procurement is intended to support an IRB-approved clinical protocol involving hepatic artery infusion therapy for oncology patients. The scope of this acquisition encompasses the initial purchase of Intera 3000 Hepatic Artery Infusion Pumps, with the contract including option line items for additional units. These options are structured to be exercised on a per-unit basis as clinical needs arise, allowing flexibility to accommodate patient enrollment and treatment requirements under the ongoing protocol. The anticipated base period of performance is from April 6, 2026, through April 5, 2027, with the possibility that option periods may be shorter, depending on clinical demand. The primary objective of this procurement is to ensure the availability of the only FDA-approved hepatic artery infusion pump suitable for the specific clinical indication addressed by the NCI’s protocol. Market research conducted by the Government has confirmed that the Intera 3000, manufactured and distributed exclusively by Inter Oncology Inc., is the sole device meeting these requirements. Substitution with any alternative device is not feasible, as no other FDA-approved products exist for this indication. Use of a non-equivalent device would introduce clinical risk, disrupt the IRB-approved protocol, and potentially compromise patient safety. Therefore, Inter Oncology Inc. is identified as the only responsible source capable of fulfilling the Government’s requirement. This procurement is being conducted under the authority of FAR Subpart 13.5, utilizing simplified procedures for certain commercial products and services, and in accordance with FAR 13.106-1(b) and 41 U.S.C. 3304(a)(1), which permit sole source awards when only one responsible source is available. The notice is classified under NAICS code 339112 (Surgical and Medical Instrument Manufacturing), with a size standard of 1,000 employees, and Product Service Code 6515 (Medical and Surgical Instruments, Equipment, and Supplies). There are no set-aside requirements associated with this procurement. The place of performance is within the United States. While this notice is not a request for competitive quotations, the Government will consider capability statements from any responsible source that believes it can provide FDA-approved hepatic artery infusion pumps meeting the stated requirements. Interested parties must submit their responses via email to the Contracting Officer, Nien-tzu Wang ([email protected]), no later than 10:00 A.M. Eastern Time on March 24, 2026. All responses will be evaluated solely to determine whether a competitive procurement is warranted; the final decision to compete the contract remains at the Government’s discretion. For further information, the primary point of contact is Nien-tzu Wang, with Marlene Milgram ([email protected]) listed as the secondary contact. The official notice and any attachments can be accessed via SAM.gov under Opportunity ID 92b0df39e5334025a628fc46a14cbe24. This procurement represents a critical and specialized requirement to support advanced oncology research and patient care, and is limited to sources capable of providing the specific FDA-approved device necessary for the protocol’s success.